USA flag logo/image

An Official Website of the United States Government

Development of a Plasma Biomarker of Alzheimer's Disease

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / STTR
Agency Tracking Number:
R41ES022893
Solicitation Year:
2012
Solicitation Topic Code:
NIEHS
Solicitation Number:
OD12-004
Small Business Information
SCOUT DIAGNOSTICS
404 CLYDEBANK COURT LOUISVILLE, KY 40243-1805
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Development of a Plasma Biomarker of Alzheimer's Disease
Agency: HHS
Contract: 1R41ES022893-01
Award Amount: $99,090.00
 

Abstract:

DESCRIPTION (provided by applicant): The major barriers to preventing or treating Alzheimer's disease (AD) are its unknown pathogenesis/etiology and the lack of an objective, sensitive and specific biomarker of the disease, particularly at the early stageswhen therapeutic interventions would likely have the greatest efficacy. The basic hypothesis of this application is that plasma levels of a novel aberrant protein/protein complex consisting or lipocalin (brain-specific) prostaglandin-d- synthase (PDS) andtransthyretin (TTR) are decreased early in disease progression and that baseline (pre-conversion) PDS/TTR levels are significantly lower in subjects who transition to mild cognitive impairment (MCI) or AD compared to normal control (NC) subjects or subjects with non-AD neurodegenerative disorders. As such, plasma PDS/TTR concentrations can be used to preferentially identify subjects who are likely to transition to MCI or AD. Preliminary analysis of antemortem plasma samples from 76 NC and 45 MCI subjects showed a statistically significant decrease of PDS/TTR levels in MCI. In addition, analysis of plasma PDS/TTR concentrations in normal subjects who later converted to MCI showed PDS/TTR concentrations before conversion were significantly (32 percent) lowerthan levels in plasma from NC subjects who remained cognitively normal during a comparable follow-up period. Although our preliminary data are promising and suggest PDS/TTR concentrations may be used to identify and predict subjects who will convert to dementia, further study is needed. To further test our hypothesis, we will analyze plasma samples from additional 80 - 100 samples from each group (NC, MCI and probable AD). We will also test whether plasma PDS/TTR complex concentrations decrease in the sameperson following conversion to MCI or AD by analyzing pre- and post-conversion specimens from NC subjects who transitioned from normal to MCI (n = 83) or AD (n = 32) compared to results obtained for plasma samples from control subjects who remained cognitively normal (n = 360) after a comparable follow-up period. Plasma specimens will also be analyzed from subjects with non-AD neurodegenerative diseases including frontotemporal dementia and diffuse Lewy body disease. In addition, we will test whether pre-conversion PDS/TTR concentrations alone, or in combination with A 1-42, A 1- 40, measures correlate with or enhance identification of MCI/AD patients based on Mini Mental State Examination (MMSE) and specific memory scores (Animal fluency, Trials A, Trials Band logical memory (logmemL)). Overall, the proposed studies, if successful, will identify and validate a novel blood based biomarker of AD that can be used to identify subjects early in disease progression when pharmacologic interventions likely have thegreatest efficacy. PUBLIC HEALTH RELEVANCE: Alzheimer's disease (AD) is the sixth leading cause of death in the United States and currently affects 4.5 million Americans. Two major barriers to treating and eventually preventing AD are: 1) the lack of understanding about the process of neuron degeneration and loss and 2) the lack of a sensitive and specific biomarker of the disease. Preliminary and future studies described in this application show that a novel protein-protein complex present in serum can be quantified using an enzyme linked immunoassay (ELISA). This protein-protein complex is a sensitive and specific biomarker of AD including early stages of AD when therapeutic interventions are most likely to have beneficial effects.

Principal Investigator:

Mark A. Lovell
859-257-1412
malove2@uky.edu

Business Contact:

John Beran
502-767-1020
jeberan@insightbb.com
Small Business Information at Submission:

SCOUT DIAGNOSTICS
404 CLYDEBANK COURT LOUISVILLE, KY 40243-1805

EIN/Tax ID: 120500937
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF KENTUCKY
UNIVERSITY OF KENTUCKY
109 KINKEAD HALL
LEXINGTON, KY 40506-0057
Contact: